BCRX Financial Facts
Basic and diluted net loss per common share: -0.16Total revenues: 7.76M
See Full Income Statement
Inventories: 2.23M
Furniture and equipment, net: 10.1M
See Full Balance Sheet
BioCryst Pharmaceuticals, Inc. (BCRX) Earnings
|
Expand Research on BCRX
| Next EPS Date | 11/3/26 *Est. | EPS Growth Rate | +100.0% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | -763.1% | Revenue Growth Rate | +33.6% *Last Qtr. |
| Average % Move 1-Wk after EPS | +2.1% | Normal Earnings Time | Before Open |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
8/5/26  |
Q226 | $0.30 | $0.16 | +$0.14 | $218.3M | $185.69M | = |  | | Details | |
| 5/6/26 | Q126 | -$2.98 | $0.05 | -$3.03 | $156.41M | $151.66M | = | | | Details | |
| 2/26/26 | Q425 | $1.12 | $0.04 | +$1.08 | $406.55M | $150.06M | = | | | Details | |
| 11/3/25 | Q325 | $0.16 | $0.05 | +$0.11 | $159.1M | $162.97M | = | | | Details | |
| 8/4/25 | Q225 | $0.15 | $0.01 | +$0.14 | $163.35M | $149.82M | = | | | Details | |
| 5/5/25 | Q125 | $0.00 | -$0.07 | +$0.07 | $134.2M | $127.91M | = | | | Details | |
| 2/24/25 | Q424 | -$0.13 | -$0.07 | -$0.06 | $131.53M | $127.17M | = | | | Details | |
| 11/4/24 | Q324 | -$0.07 | -$0.07 | $0.00 | $116.3M | $113.99M | = | | | Details |
